SCHEMBL6792937

SCHEMBL6792937

CC/C=C/c1ccc(OC(=O)CCC)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ BCL9 O00512 1/20 0.53
▸ CTNNB1 P35222 1/20 0.53
▸ KMT2A Q03164 9/20 0.50
▸ ALDH1A1 P00352 4/20 0.47
▸ MAPT P10636 3/20 0.47
▸ LMNA P02545 2/20 0.47
▸ HTT P42858 2/20 0.47
▸ HSD17B10 Q99714 1/20 0.47
▸ EGFR P00533 3/20 0.47
▸ ERBB2 P04626 3/20 0.47
▸ KDM4E B2RXH2 3/20 0.42
▸ GLA P06280 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ TTR P02766 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ CYP3A4 P08684 1/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ PDGFRB P09619 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3614705 0.83 THRB (0.58) BCL9CTNNB1KMT2AALDH1A1MAPT
SCHEMBL20581562 0.83 KMT2A (0.64) BCL9CTNNB1KMT2AALDH1A1MAPT
SCHEMBL3614708 0.83 THRB (0.58) BCL9CTNNB1KMT2AALDH1A1MAPT
SCHEMBL11023644 0.82 BCL9 (0.70) BCL9CTNNB1KMT2AALDH1A1MAPT
SCHEMBL6792463 0.82 KDM4E (0.46) BCL9CTNNB1KMT2AALDH1A1EGFR
SCHEMBL1665645 0.81 KMT2A (0.74) BCL9CTNNB1KMT2AALDH1A1MAPT
SCHEMBL6790323 0.81 MAPT (0.62) KMT2AALDH1A1MAPTLMNAHSD17B10
SCHEMBL9133021 0.81 MAPT (0.62) KMT2AALDH1A1MAPTLMNAHSD17B10
SCHEMBL17243982 0.81 LMNA (0.54) BCL9CTNNB1KMT2AALDH1A1MAPT
SCHEMBL6742672 0.81 BCL9 (0.50) BCL9CTNNB1KMT2AALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120122870-A1 Treatment Of Ischemia-Reperfusion Injury MUSC FOUNDATION FOR RESEARCH DEVELOPMENT (US) 2012-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120122870-A1 Treatment Of Ischemia-Reperfusion Injury SPHK1, SPHK2, S1PR2 BCL9 4087/4885CTNNB1 4610/4885KMT2A 4046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback